Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


NIOSH Radiation Dose Reconstruction Program


Section Navigation
			
			CDC Home








alert icon
            Cybersecurity Modernization Initiative
                We are taking steps to continue to modernize and secure our data, applications, and systems. We completed the first phase and restored many of the functions put on pause in May 2021. Now that the first phase is complete, work will resume at a slower pace but will speed up as new systems and applications are brought online. For more information and updates, please visit our Cybersecurity Modernization Initiative web page.
								

				Dow Chemical Corporation						Print
																Related Pages
										On This Page
			Special Exposure CohortAdvisory Board Work GroupTechnical DocumentsAdvisory Board and NIOSH DiscussionsProgram Evaluation Plans and Reports (PEPs and PERs)Public CommentsRelated DocumentsDocument Archive
		
(Site Profile/Docket Number 113)
Location: Madison, Illinois
Also known as: Consolidated Aluminum, Madison Site (Spectrulite), Spectrulite Consortium, Inc.
Special Exposure Cohort Petition Information
The Special Exposure Cohort (SEC) is a unique category of employees established by the Act (42 CFR Part 83). Claims compensated under the SEC do not have to go through the dose reconstruction process. To qualify for compensation under the SEC, a covered employee must meet specific requirements (e.g., must have at least one of 22 “specified cancers,” and have worked for a specified time period at one of the SEC sites). Classes of employees and work sites can be considered for addition to the SEC through a NIOSH petition process. More information about the Special Exposure Cohort can be found on our Frequently Asked Questions page.
Open/Active SEC Petitions
To date, there are no open/active SEC petitions from Dow Chemical Corporation.
Class(es) Added to the SEC
Atomic Weapons Employer (AWE) employees who were monitored or should have been monitored for exposure to thorium radionuclides while working at the Dow Chemical Company site in Madison, Illinois for a number of work days aggregating at least 250 work days from January 1, 1957 through December 31, 1960, or in combination with work days within the parameters established for one or more other classes of employees in the Special Exposure Cohort.
**Note:** This class was established from Petition 79Classes Not Added to the SEC
All Atomic Weapons Employees who worked at Dow Chemical Company in Madison, Illinois, from January 1, 1961 through November 30, 2007.
**Note:** This class was established from Petition 79Petitions Qualified for Evaluation
Below is a list of the petitions that qualified for evaluation. Select a petition on the list to view the table for that particular petition.
Petition 79 (Jan 1, 1957 to Dec 21, 1960)
	Petition 79
Steps in Petition Process:
Petition Details:Date Received
November 28, 2006Date Qualified for Evaluation
December 4, 2006Summary of Information in Petition
**Location:** Madison, Illinois
**Job Titles and/or Job Duties:** All Atomic Weapons Employer employees who were monitored, or should have been monitored, for exposure to ionizing radiation while working for a number of work days aggregating at least 250 work days, either solely under this employment or in combination with work days within the parameters established for one or more other classes of employees in the Special Exposure Cohort
**Period of Employment:** January 1, 1957 through December 21, 1960
**Note:** The information above is what qualified for evaluation. During our evaluation of whether dose reconstructions can adequately be completed for the above job titles and period of employment, information may cause NIOSH to change some the dates or job titles/duties. Therefore, as this petition proceeds through the SEC petition process and if an SEC class is proposed, the proposed class may not exactly match the above information.Copy of the Petition Received
November 28, 2006 [4.0 MB (124 pages)] (January 1, 1957 through December 31, 1960)
Attachments to the petition:
Meeting transcript from July 21, 2006 [3.5 MB (289 pages)]
Meeting transcript from August 11, 2006 [346 KB (269 pages)]
Meeting transcript from August 22, 2006 [2.5 MB (94 pages)]
Affidavits of former Dow Chemical Company employees regarding thorium [2.3 MB (46 pages)]Federal Register Notice Announcing that a Dow Chemical Company SEC Petition has met the Minimum Qualifications for Review and Evaluation
December 14, 2006 [77 KB (1 page)](January 1, 1957 through December 31, 1960)SEC Petition Evaluation Report
April 13, 2007 [127 KB (18 pages)](January 1, 1957 through December 31, 1960)
Addendum 1 August 13, 2007 [137 KB (25 pages)](January 1, 1957 through December 31, 1960)
Addendum 2 June 3, 2008 [147 KB (34 pages)] (January 1, 1957 through December 31, 1960)Evaluation Report Sent to the Advisory Board
April 13, 2007(January 1, 1957 through December 31, 1960)
August 20, 2007 (Addendum 1) (January 1, 1957 through December 31, 1960)
June 4, 2008 (Addendum 2) (January 1, 1957 through December 31, 1960)Petition Discussed by the Advisory Board
The Advisory Board discussed the petition on February 8, 2007, May 3, 2007, January 10, 2008, June 25, 2008, November 16, 2010, and February 23, 2011, during its regular meetings.
**Note:** Agendas and transcripts for Board meetings will be posted on the Advisory Board and Public Meetings page as soon as they become available.Advisory Board Recommendation on SEC Petition
May 23, 2007 [471 KB (2 pages)] (January 1, 1957 through December 31, 1960)
March 28, 2011 [42 KB (1 page)] (January 1, 1961 through November 30, 2007)HHS Letters to Congress Regarding the SEC Petition
June 22, 2007 [686 KB (6 pages)] (January 1, 1957 through December 31, 1960)
June 3, 2011 [76 KB (9 pages)] (January 1, 1961 through November 30, 2007)HHS Designation/Determination of Additional Members to the SEC
**Designation:**
June 22, 2007 [461 KB (4 pages)] (January 1, 1957 through December 31, 1960)
**Determination:**
June 3, 2011 [102 KB (4 pages)] (January 1, 1961 through November 30, 2007)
**Note:** A “designation” means that HHS is recommending a class be added to the SEC. A “determination” means that HHS is recommending a class **not** be added to the SEC.Federal Register Notice: Designation/Determination of a Class of Employees for Addition to the Special Exposure Cohort
**Designation:**
August 7, 2007 [149 KB (2 pages)] (January 1, 1957 through December 31, 1960)
**Determination:**
June 24, 2011 [59 KB (2 pages)] (January 1, 1961 through November 30, 2007)
**Note:** A “designation” will be published if there is a recommendation to add a class to the SEC. A “determination” will be published if there is a recommendation **not** to add a class to the SEC.Effective Date for the SEC Class
July 22, 2007 (January 1, 1957 through December 31, 1960)
**Note:** This only applies if the class is added to the SEC.Federal Register Notice: Final Effect of Designation of a Class of Employees for Addition to the Special Exposure Cohort
August 7, 2007 [79 KB (1 page)] (January 1, 1957 through December 31, 1960)
**Note:** This only applies if the class is added to the SEC.Letter to DOL Regarding the Addition of a New Class of Employees to the SEC
July 30, 2007 [25 KB (1 page)] (January 1, 1957 through December 31, 1960)
**Note:** This only applies if the class is added to the SEC.
Advisory Board Work Group on Dow Chemical Corporation
This Work Group is responsible for the review of TBDs and SEC petitions for uranium refining AWEs as assigned to it by the Board. It will also review any reports developed by the Board’s contractor (SC&A) pertaining to these TBDs and SEC petitions, and will assist NIOSH and SC&A in resolving issues that arise through the review process. The Work Group will make recommendations to the Board regarding such SEC petitions. Sites currently being considered by the Work Group include Baker-Perkins Co., Du Pont Deepwater Works, Electro Metallurgical, Hooker Electrochemical, and United Nuclear Corp.
Work Group Members
James Malcolm Melius, M.D., Dr. P.H.-Chair
Josie Beach
Genevieve S. Roessler, Ph.D.
Paul L. Ziemer, Ph.D.Meeting Information:
**November 12, 2010** Teleconference Meeting of the Advisory Board’s Work Group on SEC Issues (including the 250 day issue) Work Group
Time/Location:
1:00 p.m. Eastern Standard Time (EST) Meeting Type: Teleconference; Public, No Comment Period
Teleconference: +1-866-659-0537 Participant Code: 9933701
Pre-Decisional Document Policy
Available Meeting Items:
Agenda [10 KB (1 page)]
Transcript [175 KB (83 pages)]
**May 11, 2010** Meeting of the Advisory Board’s Work Group on SEC Issues (including the 250 day issue)
Time/Location:
10:00 a.m. Eastern Standard Time (EST) Meeting Type: Face-to-Face; Public, No Comment Period
Cincinnati Airport Marriott 2395 Progress Dr. Hebron, KY 41048 Phone: (859) 586-0166
Teleconference: +1-866-659-0537 Participant Code: 9933701
Pre-Decisional Document Policy
Available Meeting Items:
Agenda [8 KB (1 page)]
Transcript [428 KB (203 pages)]
**February 5, 2010** Teleconference Meeting of the Advisory Board’s Work Group on SEC Issues (including the 250 day issue)
10:00 a.m. Eastern Standard Time (EST) Meeting Type: Teleconference; Public, No Comment Period
Teleconference: +1-866-659-0537 Participant Code: 9933701
Pre-Decisional Document Policy
Available Meeting Items:
Agenda [11 KB (1 page)]
Transcript [262 KB (117 pages)]
**July 24, 2009** Teleconference Meeting of the Advisory Board’s Work Group on SEC Issues (including the 250 day issue)
Time/Location:
3:00 p.m. Eastern Standard Time (EST) Meeting Type: Teleconference; Public, No Comment Period
Teleconference: +1-866-659-0537 Participant Code: 9933701
Pre-Decisional Document Policy
Available Meeting Items:
Agenda [8 KB (1 page)]
Transcript [228 KB (101 pages)]
**November 17, 2008** Meeting of the Advisory Board’s Work Group on SEC Issues
Time/Location:
9:30 a.m. Eastern Standard Time (EST) Meeting Type: Face-to-Face; Public, No Comment Period
Cincinnati Airport Marriott 2395 Progress Dr. Hebron, KY 41048 Phone: (859) 586-0166
Teleconference: +1-866-659-0537 Participant Code: 9933701
Pre-Decisional Document Policy
Available Meeting Items:
An agenda will be provided at a later date.
Transcript [2 MB (150 pages)]Pre-Decisional Document Policy
Please note that as part of the procedures and processes of the Advisory Board’s Work Groups, several kinds of pre-decisional documents may be developed. These pre-decisional documents, such as white papers, matrices, working drafts, etc., are distributed among Work Group members as research and background tools to facilitate discussion and deliberation. Although discussion during a public meeting may cover pre-decisional documents, these documents often are not further revised or finalized, and thus do not reflect the final determination or evaluation of the Advisory Board and its Work Groups. Additionally, some pre-decisional documents not otherwise posted on the website may contain sensitive information, which would require an interested party to obtain such documents by filing a Freedom of Information Act (FOIA) request with the CDC/ATSDR FOIA office at foiarequests@cdc.gov.
Technical Documents
If the energy employee’s personal radiation information is incomplete, NIOSH will use other sources to estimate the radiation dose. This may involve using technical documents called Site Profiles, Technical Basis Documents, and Technical Information Bulletins.
Site Profile
Site Profile for Atomic Weapons Employers that Worked Uranium Metals [942 KB (55 pages)]
Revised June 17, 2011
Previously titled “Site Profile for Atomic Weapons Employers that Worked Uranium and Thorium Metals”
**About this Document:** This document provides an exposure matrix for workers at AWE facilities that performed metal-working operations with uranium metal. Over 110 facilities performed these operations, and this document intends to provide guidance for dose reconstruction at any of these facilities. The main body of this document, in Sections 2-6, includes general discussions of operations and exposure conditions at these facilities. Following the main body of this document is a collection of appendices, with one appendix for each AWE site that performed metal-working operations. Each appendix contains site-specific information that can be used for dose reconstruction. For those sites where this information is insufficient or totally lacking, the dose reconstructor must use information in the main body of the Site Profile.
**Revision Includes:** Incorporates review comments. Added external beta dose from surface contamination. Expanded discussion in section 3.3.1. Additional editorial changes and typographical error corrections.
Appendices:
Appendix C — Dow Chemical Company (Madison Site) [373 KB (18 pages)] Revised April 3, 2014Advisory Board and NIOSH Discussions on Dow Chemical Corporation
The Dow Chemical Corporation (Madison Site) discussion papers listed below are working documents prepared by NIOSH or its contractor for use in discussions with the Advisory Board on Radiation and Worker Health or its Working Groups or Subcommittees. Draft, preliminary, interim, and white paper documents are not final NIOSH or Advisory Board (or their technical support and review contractors) positions unless specifically marked as such. These documents represent preliminary positions taken on technical issues prepared by NIOSH or its contractor.
The discussion papers have been reviewed to identify and redact any information that is protected by the Privacy Act 5 USC §552a and have been cleared for distribution.
SC&A Draft: Focused Review of Appendix C, Revision 1 to TBD-6000, Dow Chemical Company (Madison Site) [463 KB (22 pages)] Contract No. 211-2014-58081 SCA-TR-SP2015-0051, Revision 0 April 9, 2015
Draft: Evolution of Dose Reconstruction Approach at Dow Madison and Use of Surrogate Data [42 KB (7 pages)]
                        Contract No. 200-2009-28555
                        March 2010
Draft: Resolution of SC&A Findings on Appendix C (Dow Madison) of Battelle-TBD-6000 [31 KB (5 pages)]
                        Contract No. 200-2009-28555
                        March 2010
Draft: Focused Review of Appendix C to TBD-6000–Dow Chemical Company (Madison Site) [151 KB (18 pages)]
                        Contract No. 200-2009-28555
                        August 2009
Draft: Addendum 2. A Focused Review of Addendum 2 to the Dow Chemical – Madison Plant SEC Petition Evaluation Report [270 KB (22 pages)]
                        Contract No. 200-2004-03805
                        Task Order No. 5
                        September 2008
Draft: A Focused Review of Operations and Thorium Exposures at the Dow Chemical Company Madison Plant [862 KB (66 pages)]
                        Contract No. 200-2004-03805
                        Task Order No. 5
                        August 2007Program Evaluation Plans (PEPs) and Program Evaluation Reports (PERs)
NIOSH is committed to applying the best available science in dose reconstructions. In keeping with this commitment, completed cases with probabilities of causation less than 50% are reviewed as relevant new information becomes available. The results of these reviews are described in a Program Evaluation Report (PER). The PER details the effect, if any, of the new information on the completed dose reconstruction. If it appears that the new information may result in an increase in dose for a completed dose reconstruction with a probability of causation of less than 50%, NIOSH is committed to working with the Department of Labor to reopen and rework the dose reconstruction, as appropriate. A Program Evaluation Plan (PEP) describes plans for evaluating specific program details or issues.
DCAS-PER-058: Dow Chemical Co.–Madison Site [20 KB 2 pages)] November 21, 2014
**About this Document:** Determines the effect on previously completed claims due to a revision to the Dow Chemical Appendix.
**Summary:** None of the claims resulted in a POC greater than 50%. NIOSH will provide the Department of Labor with the list of all the claims evaluated under this PER.Public Comments on Dow Chemical Corporation Documents
How to Submit Comments
Comments on Dow Chemical Corporation Documents can be submitted to the NIOSH Docket Officer electronically by email at nioshdocket@cdc.gov or printed comments can be mailed to:
NIOSH Docket Office Robert A. Taft Laboratories, MS-C34 1090 Tusculum Avenue Cincinnati, OH 45226 Please include the Site Profile/Docket Number (113) on all comments.
Comments Received
Submission from Daniel W. McKeel, Jr., M.D., regarding NIOSH, DOL, and DOE website data for Dow Chemical Corporation (CA and Madison sites) and SEC petition class size (operational and residual periods) for General Steel Industries Special Exposure Cohort Petition SEC-00105 [3 MB (27 pages)] March 27, 2015
Comments from Daniel W. McKeel, Jr., M.D., on the Dow Chemical Co. (Madison Site) SEC Petition (NIOSH SEC-00079) [2 MB (3 pages)] February 12, 2011  
Attachment [88 KB (4 pages)]
Comments from Daniel W. McKeel, Jr., M.D., on the Dow Chemical Co. (Madison Site) SEC Petition (NIOSH SEC-00079) [2.1 MB (3 pages)] February 11, 2011  
Attachment 1 [831 KB (23 pages)]
Attachment 2 [141 KB (70 pages)]
Comments from Daniel W. McKeel, Jr., M.D., on the Dow Chemical Co. (Madison Site) SEC Petition (NIOSH SEC-00079) [1.6 MB (108 pages)] July 12, 2010
Comments from Daniel W. McKeel, Jr., M.D., on the Dow Chemical Co. (Madison Site) SEC Petition (NIOSH SEC-00079) [4.4 MB (27 pages)] June 13, 2010
Comments from Daniel W. McKeel, Jr., M.D., on the Former Dow Chemical, Madison, IL, AWE Facility, Including NIOSH Addendum 2 to the NIOSH SEC-00079 Evaluation; SC&A Review of Addendum 2; Appendix C to TBD-6000 and the SC&A Review of Appendix C [537 KB (15 pages)] May 11, 2010
Draft: Evolution of Dose Reconstruction Approach at Dow Madison and Use of Surrogate Data [37 KB (7 pages)] Contract No. 200-2009-28555 March 2010
Draft: Resolution of SC&A Findings on Appendix C (Dow Madison) of Battelle-TBD-6000 [26 KB (5 pages)] Contract No. 200-2009-28555 March 2010
Draft: Focused Review of Appendix C to TBD-6000–Dow Chemical Company (Madison Site) [106 KB (18 pages)] Contract No. 200-2009-28555 August 2009
Draft: Addendum 2. A Focused Review of Addendum 2 to the Dow Chemical – Madison Plant SEC Petition Evaluation Report [153 KB (22 pages)] Contract No. 200-2004-03805 Task Order No. 5 September 2008
Draft: A Focused Review of Operations and Thorium Exposures at the Dow Chemical Company Madison Plant [784 KB (66 pages)] Contract No. 200-2004-03805 Task Order No. 5 August 2007Documents Related to Dow Chemical Corporation
Dow Worker Outreach Meeting Transcript from June 20, 2007, taken by SimmonsCooper, LLC [4 MB (131 pages)]
Draft: A Focused Review of Operations and Thorium Exposures at the Dow Chemical Company Madison Plant [784 KB (66 pages)] Contract No. 200-2004-03805 Task Order No. 5 August 2007
Letter from Senator Barack Obama to Elizabeth White (DOE) requesting documentation related to the relationship between the former Dow Chemical Company, the Atomic Energy Commission, and the Rocky Flats Plant. [50 KB (3 pages)]
Letter from Roger Anders (DOE) to Larry Elliott regarding information in DOE’s response to Senator Barack Obama’s letter to Elizabeth White (DOE) requesting documentation related to the relationship between the former Dow Chemical Company, the Atomic Energy Commission, and the Rocky Flats Plant for an Advisory Board meeting. [46 KB (2 pages)] 
Category 2, Item 1 [183 KB (4 pages)]
Category 2, Item 2 [24 KB (1 page)]
Category 3, Item 1 [225 KB (10 pages)]
Category 3, Item 2 [279 KB (4 pages)]
Category 3, Item 3 [151 KB (3 pages)]
Category 4 [259 KB (6 pages)]
Category 5 [63 KB (2 pages)]
Category 9 [622 KB (13 pages)]Document Archive for Dow Chemical Corporation
Site Profile for Atomic Weapons Employers that Worked Uranium and Thorium Metals [1.2 MB (57 pages)] Approved December 13, 2006
**About this Document:** This document provides an exposure matrix for workers at AWE facilities that performed metal-working operations with uranium metal. Over 110 facilities performed these operations, and this document intends to provide guidance for dose reconstruction at any of these facilities. The main body of this document, in Sections 2-6, includes general discussions of operations and exposure conditions at these facilities. Following the main body of this document is a collection of appendices, with one appendix for each AWE site that performed metal-working operations. Each appendix contains site-specific information that can be used for dose reconstruction. For those sites where this information is insufficient or totally lacking, the dose reconstructor must use information in the main body of the Site Profile.
Appendix C — Dow Chemical Company (Madison Site) [146 KB (13 pages)] Approved September 8, 2008
							
					
							Last Reviewed:  June 30, 2022						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate homeRadiation Dose ReconstructionAbout DCASThe Act/EEOICPADose Reconstruction (DR)plus iconDataplus iconSourcesFormats & TypesSensitive DataWork History                            Phone CallData Search and Capture EffortsMethodsProductionTechnical Documents Used in Dose ReconstructionsProgram Evaluation Reports and PlansQuality Assurance and Quality ControlSupport ContractorSoftware (IMBA)RECA ClaimsProbability of Causationplus iconCalculating PCNews & UpdatesNIOSH-IREP SoftwareSpecial Exposure Cohortplus iconSubmit a PetitionCheck Petition Statusplus iconSEC Status TableGet HelpResidual ContaminationAdvisory Boardplus iconPublic MeetingsSubcommittee and Work GroupsSEC Petition RecommendationsTechnical Support for the Review of NIOSH Dose Reconstruction ProgramReports from the Advisory Board's Technical Support ContractorTechnical Review Summaries from the Technical Support ContractorProceduresCorrespondenceWork Site InformationPublications & ProductsProgram ReviewsReports to CongressPolicies, Procedures, and GuidelinesNIOSH Public DocketRelated Program LinksContact UsHELPplus iconHelp A – ZAccessibilityAcronymsFrequently Asked Questions (FAQs)plus iconThe ActCase ConcernsClaimant CorrespondenceConflict or BiasDose ReconstructionFreedom of Information Act (FOIA)National Defense Authorization ActNIOSH-IREPProbability of CausationResidual Contamination ReportResponsibilities under Subtitle B of EEOICPA (The Act)Special Exposure CohortTechnical DocumentsWork History Phone CallGlossary Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue